Navigation Links
First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
Date:11/29/2007

Ophthalmic Clinic in Germany First in Europe To Treat Patients With New

Focused Radiation Therapy

LEIPZIG, Germany, November 29 /PRNewswire/ -- NeoVista, Inc. announced today that the first European patient has been treated in the company's pivotal global clinical trial for its novel beta radiation epiretinal therapy for the wet form of age-related macular degeneration (AMD). Wet AMD is the most progressive form of AMD and one of the leading causes of blindness in the industrialized world for patients over 50. Unlike the current standard of care which requires costly monthly eye injections, NeoVista's investigational therapy delivers a one-time dose of radiation providing a less invasive and potentially more cost-effective treatment option.

The procedure was performed as part of NeoVista's CABERNET (CNV Secondary to AMD Treated with BEta RaditioN Epiretinal Therapy) trial, which seeks to enroll a total of 450 patients (300 in the radiation treatment arm) in approximately 40 sites worldwide to evaluate the efficacy and safety of NeoVista's novel radiation therapy. Patients in the study receive a single treatment with NeoVista's targeted radiation in combination with an injection of Lucentis(R) at the time of radiation delivery to maximize immediate effect.

"We're excited to have the opportunity to try this innovative technique with our patients. NeoVista's targeted radiation treatment may provide us the ability to improve vision for the elderly and dramatically change their quality of life by eliminating frequent eye injections," said Christian Foja, MD Leipzig University Eye Hospital, who performed the procedure.

Peter Wiedemann, MD, who oversees the department at Leipzig University Eye Hospital, echoed Dr. Foja's sentiments. "NeoVista is developing a promising new wet AMD treatment that could also be a cost-effective alternative in Europe," said Dr. Wiedemann. "And without having to perform regular, monthl
'/>"/>

SOURCE NeoVista, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... 14, 2014 Carahsoft and CDS Federal ... 23, 2014 at 2pm EST (11am PST), “Natural Language ... focuses on how technology can turn raw, heterogeneous data ... government agencies. The online webinar will last approximately one ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Tornado-Torn ... Health Care Facility, MALVERN, Pa., Jan. ... a devastating 2007 tornado,Siemens has announced that, as part of its ... new MAGNETOM ESSENZA, worth,approximately $800,000., Siemens took notice of Sumter,s ...
... talent and investors to state, TOPEKA, Kan., ... announced today a "Come Home to Kansas" initiative ... investors to Kansas. Partners in this project include ... the Kansas,Bioscience Organization and the KTEC PIPELINE., ...
... Inc.,(Nasdaq: CRDC ) today reported financial results ... and six months ended December 31, 2007., ... over 1,000,C-Port systems shipped in the past quarter ... to enable minimally-invasive cardiac surgery and,substantial advancement for ...
Cached Biology Technology:A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens 2'Come Home to Kansas' Announced by KTEC 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7
(Date:4/18/2014)... emergency contraceptive pills in Peru found that 28 ... substandard quality or falsified. Many pills released the ... active ingredient. One batch had no active ingredient ... drugs, researchers at the Georgia Institute of Technology ... quickly assess suspected counterfeit drugs and then characterize ...
(Date:4/18/2014)... Ancient DNA adds a twist to the story of how ... published April 21 in the journal Proceedings of the ... bones of chickens that lived 200-2300 years ago in Europe, ... chickens may have looked far different from the chickens we ... traits we associate with modern domestic chickens -- such as ...
(Date:4/17/2014)... 17 In the most densely forested and most ... two centuries of human needs, values and practices. Disturbances ... forests for agriculture and development, have set the stage ... Forest Service study reports. , The report Five ... management needs in the Northern United States ...
Breaking Biology News(10 mins):Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
... MANHATTAN, Kan. -- If cats really had nine lives, one ... of diseases that threaten feline health. Yunjeong Kim, a ... Kansas State University, has developed a research approach that tackles ... work is being supported by a $156,342 award from the ...
... ensure that the benefits of genetic resources are shared in ... the Convention on Biological Diversity, though questions remain about how ... new report from the Synthetic Biology Project at the Woodrow ... may affect U.S. researchers working in the field of synthetic ...
... (4 November 2013) The Population Council, an international ... development issues, will present findings from more than 40 ... Addis Ababa, Ethiopia (November 12-15, 2013). Notable ... in programs that strengthen gender equity; improve financing mechanisms ...
Cached Biology News:College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases 2College of Veterinary Medicine researcher doubles down on deadly, infectious cat diseases 3Population Council to present more than 40 studies at International Conference on Family Planning 2Population Council to present more than 40 studies at International Conference on Family Planning 3Population Council to present more than 40 studies at International Conference on Family Planning 4
MOUSE ANTI RAT RT1Bu Immunogen: Rat thymocyte membrane glycoproteins...
RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
RABBIT ANTI HUMAN APP (KP1 DOMAIN) Immunogen: Synthetic peptide composed of amino acids 292-312 from the KPI domain of human APP....
... The Light Diagnostics Cytomegalovirus (CMV) pp65 Antigenemia ... qualitative identification of lower matrix protein pp65 ... Kit Components: ... One bottle containing 220 mL of buffered ...
Biology Products: